Boiron (FRA:BON) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BON Boiron SA FRA:BON
76 GF Score
Price €27.10
GF Value €33.55
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Boiron FFO per Share?

FFO per Share only applies to REITs.

FRA:BON
76GF Score
Boiron SA FRA:BON
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (FRA:BON) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of €27.10 is trading 19.2% below its estimated GF Value™ of €33.55. GuruFocus considers Boiron to be Modestly Undervalued.

Key valuation signals for FRA:BON:

  • FFO per Share:
  • GF Value™: €33.55 vs. price of €27.10 (19.2% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the FRA:BON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Other Exchanges BOIRF:USA0DTF:UKBOI:France
Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
76GF Score

Get the complete analysis for FRA:BON

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.10
Price
€33.55
GF Value